News
Merck Gets FDA Approval for Respiratory Treatment for Infants
The company said Monday the approval is based on results from its Phase 2b/3 trial evaluating a single dose of the treatment for infants up to one year old. The trial showed about a 61% reduction in RSV-associated lower respiratory infections or severity compared to a placebo through 5 months.
THURSDAY, June 12, 2025 (HealthDay News) — A newly approved shot could soon help protect babies from respiratory syncytial ...
The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 ...
Rep Kim Schrier, MD, (D-Wash.), said on X yesterday that some of the newly appointed ACIP replacements are anti-vaccine ...
The number of Australians vaccinated against influenza is "worryingly low", health experts say, as new data reveal the winter ...
News-Medical.Net on MSN13d
WHO releases first-ever position paper on immunization products to protect infants against RSVToday, the World Health Organization (WHO) published its first-ever position paper on immunization products to protect ...
Estimates varied from 2008 through 2018, with RSV-associated antibiotic prescribing exceeding 10% in peak RSV years and ...
Scientists and analysts express concern that the newly appointed members—which include known anti-vaxxers—could relitigate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback